vs

Side-by-side financial comparison of INTEST CORP (INTT) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.

Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $32.8M, roughly 1.8× INTEST CORP). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -10.3%). INTEST CORP produced more free cash flow last quarter ($-1.6M vs $-167.0M).

INTTEST Corp designs, manufactures and distributes precision test and process control solutions for the global semiconductor manufacturing ecosystem. Its offerings include thermal management systems, test interface hardware, and wafer handling tools, serving semiconductor fabs, chip design firms, and automotive and industrial electronics end segments.

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

INTT vs PHAT — Head-to-Head

Bigger by revenue
PHAT
PHAT
1.8× larger
PHAT
$57.6M
$32.8M
INTT
Growing faster (revenue YoY)
PHAT
PHAT
+104.5% gap
PHAT
94.1%
-10.3%
INTT
More free cash flow
INTT
INTT
$165.4M more FCF
INTT
$-1.6M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INTT
INTT
PHAT
PHAT
Revenue
$32.8M
$57.6M
Net Profit
$1.2M
Gross Margin
45.4%
86.7%
Operating Margin
3.9%
Net Margin
3.8%
Revenue YoY
-10.3%
94.1%
Net Profit YoY
-17.4%
71.6%
EPS (diluted)
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INTT
INTT
PHAT
PHAT
Q4 25
$32.8M
$57.6M
Q3 25
$26.2M
$49.5M
Q2 25
$28.1M
$39.5M
Q1 25
$26.6M
$28.5M
Q4 24
$36.6M
$29.7M
Q3 24
$30.3M
$16.4M
Q2 24
$34.0M
$7.3M
Q1 24
$29.8M
Net Profit
INTT
INTT
PHAT
PHAT
Q4 25
$1.2M
Q3 25
$-938.0K
$-30.0M
Q2 25
$-503.0K
$-75.8M
Q1 25
$-2.3M
$-94.3M
Q4 24
$1.5M
Q3 24
$495.0K
$-85.6M
Q2 24
$230.0K
$-91.4M
Q1 24
$662.0K
Gross Margin
INTT
INTT
PHAT
PHAT
Q4 25
45.4%
86.7%
Q3 25
41.9%
87.5%
Q2 25
42.6%
87.2%
Q1 25
41.5%
86.9%
Q4 24
39.7%
87.1%
Q3 24
46.3%
85.6%
Q2 24
40.6%
81.2%
Q1 24
43.8%
Operating Margin
INTT
INTT
PHAT
PHAT
Q4 25
3.9%
Q3 25
-4.5%
-30.8%
Q2 25
-3.3%
-151.7%
Q1 25
-10.8%
-276.5%
Q4 24
5.7%
Q3 24
1.6%
-433.0%
Q2 24
1.0%
-1055.4%
Q1 24
1.6%
Net Margin
INTT
INTT
PHAT
PHAT
Q4 25
3.8%
Q3 25
-3.6%
-60.5%
Q2 25
-1.8%
-191.9%
Q1 25
-8.7%
-330.7%
Q4 24
4.1%
Q3 24
1.6%
-523.3%
Q2 24
0.7%
-1248.6%
Q1 24
2.2%
EPS (diluted)
INTT
INTT
PHAT
PHAT
Q4 25
$0.10
Q3 25
$-0.08
$-0.41
Q2 25
$-0.04
$-1.05
Q1 25
$-0.19
$-1.31
Q4 24
$0.13
Q3 24
$0.04
$-1.32
Q2 24
$0.02
$-1.56
Q1 24
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INTT
INTT
PHAT
PHAT
Cash + ST InvestmentsLiquidity on hand
$14.2M
$130.0M
Total DebtLower is stronger
$209.1M
Stockholders' EquityBook value
$103.6M
$-438.2M
Total Assets
$151.3M
$259.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INTT
INTT
PHAT
PHAT
Q4 25
$14.2M
$130.0M
Q3 25
$16.2M
$135.2M
Q2 25
$19.2M
$149.6M
Q1 25
$22.0M
$212.3M
Q4 24
$19.8M
$297.3M
Q3 24
$18.0M
$334.7M
Q2 24
$20.4M
$276.2M
Q1 24
$27.3M
Total Debt
INTT
INTT
PHAT
PHAT
Q4 25
$209.1M
Q3 25
$4.9M
$207.1M
Q2 25
$5.9M
$205.1M
Q1 25
$6.9M
$203.2M
Q4 24
$7.9M
$201.4M
Q3 24
$9.0M
$175.7M
Q2 24
$10.0M
$174.4M
Q1 24
$11.0M
Stockholders' Equity
INTT
INTT
PHAT
PHAT
Q4 25
$103.6M
$-438.2M
Q3 25
$101.9M
$-422.5M
Q2 25
$102.6M
$-405.8M
Q1 25
$99.4M
$-338.4M
Q4 24
$99.8M
$-253.6M
Q3 24
$100.4M
$-187.1M
Q2 24
$99.5M
$-233.8M
Q1 24
$99.3M
Total Assets
INTT
INTT
PHAT
PHAT
Q4 25
$151.3M
$259.1M
Q3 25
$148.3M
$240.3M
Q2 25
$149.7M
$250.2M
Q1 25
$148.0M
$294.2M
Q4 24
$152.3M
$378.3M
Q3 24
$158.4M
$387.0M
Q2 24
$160.6M
$319.4M
Q1 24
$159.5M
Debt / Equity
INTT
INTT
PHAT
PHAT
Q4 25
Q3 25
0.05×
Q2 25
0.06×
Q1 25
0.07×
Q4 24
0.08×
Q3 24
0.09×
Q2 24
0.10×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INTT
INTT
PHAT
PHAT
Operating Cash FlowLast quarter
$-1.0M
$-166.8M
Free Cash FlowOCF − Capex
$-1.6M
$-167.0M
FCF MarginFCF / Revenue
-4.7%
-290.0%
Capex IntensityCapex / Revenue
1.6%
0.4%
Cash ConversionOCF / Net Profit
-0.82×
TTM Free Cash FlowTrailing 4 quarters
$5.7M
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INTT
INTT
PHAT
PHAT
Q4 25
$-1.0M
$-166.8M
Q3 25
$3.5M
$-14.1M
Q2 25
$-688.0K
$-62.7M
Q1 25
$5.5M
$-84.9M
Q4 24
$2.6M
$-266.8M
Q3 24
$4.2M
$-63.6M
Q2 24
$-5.1M
$-70.7M
Q1 24
$2.1M
Free Cash Flow
INTT
INTT
PHAT
PHAT
Q4 25
$-1.6M
$-167.0M
Q3 25
$3.1M
$-14.1M
Q2 25
$-1.1M
$-62.8M
Q1 25
$5.3M
$-84.9M
Q4 24
$2.4M
$-266.9M
Q3 24
$3.7M
$-63.6M
Q2 24
$-5.4M
$-70.8M
Q1 24
$1.7M
FCF Margin
INTT
INTT
PHAT
PHAT
Q4 25
-4.7%
-290.0%
Q3 25
11.8%
-28.6%
Q2 25
-4.1%
-159.0%
Q1 25
19.9%
-297.9%
Q4 24
6.6%
-899.8%
Q3 24
12.4%
-389.0%
Q2 24
-15.9%
-966.2%
Q1 24
5.8%
Capex Intensity
INTT
INTT
PHAT
PHAT
Q4 25
1.6%
0.4%
Q3 25
1.6%
0.1%
Q2 25
1.6%
0.2%
Q1 25
0.9%
0.1%
Q4 24
0.4%
0.5%
Q3 24
1.7%
0.3%
Q2 24
0.9%
0.6%
Q1 24
1.1%
Cash Conversion
INTT
INTT
PHAT
PHAT
Q4 25
-0.82×
Q3 25
Q2 25
Q1 25
Q4 24
1.72×
Q3 24
8.58×
Q2 24
-22.13×
Q1 24
3.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INTT
INTT

Environmental Technologies$8.3M25%
Semiconductor Market$6.9M21%
Thermal Testing Products$6.4M19%
Service And Other Products$4.8M15%
Oem Integrators And Distributor$3.5M11%
Semiconductor Production Test Products$3.0M9%

PHAT
PHAT

Segment breakdown not available.

Related Comparisons